<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450216</url>
  </required_header>
  <id_info>
    <org_study_id>HZ-CA-303</org_study_id>
    <nct_id>NCT00450216</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment</brief_title>
  <official_title>A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizon Pharma Ireland, Ltd., Dublin Ireland</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Horizon Pharma Ireland, Ltd., Dublin Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of
      development of ibuprofen-associated ulcers in patients who require long-term daily use of
      ibuprofen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine.
      The study is designed to determine whether the combination product reduces the rate of ulcer
      development in subjects who require long-term daily use of ibuprofen.

      Subjects will be assigned randomly, in approximately a 2:1 ratio, to treatment with either
      HZT-501 (ibuprofen 800 mg/famotidine 26.6 mg) or ibuprofen (800 mg) three times daily for a
      24 week treatment period or until they develop either an endoscopically-diagnosed upper
      gastrointestinal ulcer and/or prohibitive toxicity. Subjects will visit the study center for
      Screening and at Weeks 4, 8, 16, and 24. Physical exams will be performed, and clinical
      laboratory measurements made, at selected times during the study. Endoscopic exams will be
      performed during Screening and at Weeks 8, 16, and 24. Subjects will be contacted four weeks
      following study completion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Developing Non-steroidal Anti-inflammatory (NSAID)Associated Serious Gastrointestinal Complications (Perforation of Ulcers, Gastric Outlet Obstruction Due to Ulcers, Gastrointestinal Bleeding)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">906</enrollment>
  <condition>Ulcer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HZT-501: Ibuprofen 800mg/famotidine 26.6mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 800mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen/famotidine</intervention_name>
    <description>HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen 800mg administered orally 3 times daily for 24 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Expected to require daily administration of an NSAID for at least the coming six
             months for conditions such as osteoarthritis, rheumatoid arthritis, chronic low back
             pain, chronic regional pain syndrome, and chronic soft tissue pain.

          -  Did not use a NSAID within the 30 days prior to study entry

        Exclusion Criteria:

          -  History of erosive esophagitis

          -  History of any of the following serious gastrointestinal complications:

               -  perforation of ulcers,

               -  gastric outlet obstruction due to ulcers, or

               -  gastrointestinal bleeding.

          -  Active cardiac, renal, and/or hepatic disease

          -  Current Helicobacter pylori (H. pylori) infection

          -  Use of an acid suppressant agent, misoprostol, or more than 325 mg/day of aspirin
             within the 14 days prior to study entry.

          -  Uncontrolled diabetes

          -  Uncontrolled hypertension

          -  Positive pregnancy test at screening

          -  Positive test at Screening for human immunodeficiency virus (HIV), hepatitis B, or
             hepatitis C.

          -  Currently participating, or participation within 30 days prior to study entry, in an
             investigational drug study

        Please note that there are other additional criteria. The study center will determine if
        patients meet all of the criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2007</study_first_submitted>
  <study_first_submitted_qc>March 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <results_first_submitted>May 17, 2011</results_first_submitted>
  <results_first_submitted_qc>May 17, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 21, 2011</results_first_posted>
  <last_update_submitted>April 22, 2013</last_update_submitted>
  <last_update_submitted_qc>April 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ibuprofen</keyword>
  <keyword>famotidine</keyword>
  <keyword>ulcers</keyword>
  <keyword>NSAIDS</keyword>
  <keyword>pain</keyword>
  <keyword>arthritis</keyword>
  <keyword>chronic regional pain syndrome</keyword>
  <keyword>chronic soft tissue pain</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>chronic low back pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HZT-501</title>
          <description>HZT-501: Ibuprofen 800mg/famotidine 26.6mg tablets t.i.d.</description>
        </group>
        <group group_id="P2">
          <title>Ibuprofen</title>
          <description>Ibuprofen 800mg tablets t.i.d.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="607"/>
                <participants group_id="P2" count="299"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="433"/>
                <participants group_id="P2" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>upper gastrointestinal (UGI) ulcer</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>misc</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HZT-501</title>
          <description>HZT-501: Ibuprofen 800mg/famotidine 26.6mg</description>
        </group>
        <group group_id="B2">
          <title>Ibuprofen</title>
          <description>Ibuprofen 800mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="607"/>
            <count group_id="B2" value="299"/>
            <count group_id="B3" value="906"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" spread="9.2"/>
                    <measurement group_id="B2" value="55.9" spread="9.3"/>
                    <measurement group_id="B3" value="55.6" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="416"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="607"/>
                    <measurement group_id="B2" value="299"/>
                    <measurement group_id="B3" value="906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers</title>
        <description>The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.</description>
        <time_frame>24 weeks</time_frame>
        <population>All randomized participants who received at least one dose of study drug and who underwent a baseline endoscopic examination and at least the Week 8 endoscopic examination. Participants were assigned according to the treatment to which they were randomized; 2:1 randomization, HZT-501:ibuprofen.</population>
        <group_list>
          <group group_id="O1">
            <title>HZT-501</title>
            <description>HZT-501: Ibuprofen 800mg/famotidine 26.6mg</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 800mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers</title>
          <description>The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.</description>
          <population>All randomized participants who received at least one dose of study drug and who underwent a baseline endoscopic examination and at least the Week 8 endoscopic examination. Participants were assigned according to the treatment to which they were randomized; 2:1 randomization, HZT-501:ibuprofen.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="550"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="4.4" upper_limit="15.3"/>
                    <measurement group_id="O2" value="52" lower_limit="4.4" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy endpoint was the number of participants developing gastric ulcers throughout 24 weeks of treatment. A summary, including cumulative frequency and percentage with associated 95% confidence intervals was produced for the observational incidences of gastric ulcers at 24 weeks. The cumulative number of participants developing gastric ulcers at 24 weeks was analyzed using the Cochran-Mantel-Haenszel (CMH) test stratified by use of low-dose aspirin and prior UGI ulcer history.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>CMH test stratified by use of low-dose aspirin (yes/no) and prior upper gastrointestinal (UGI) ulcer history (yes/no) at randomization.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>9.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.4</ci_lower_limit>
            <ci_upper_limit>15.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period.</title>
        <description>The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HZT-501</title>
            <description>HZT-501: Ibuprofen 800mg/famotidine 26.6mg</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 800mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period.</title>
          <description>The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="550"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="6.1" upper_limit="17.6"/>
                    <measurement group_id="O2" value="61" lower_limit="6.1" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The secondary efficacy endpoint was the number of participants developing UGI (i.e., gastric and/or duodenal) ulcers throughout 24 weeks of treatment. A summary, including cumulative frequency and percentage with associated 95% confidence intervals was produced for the observational incidences of UGI ulcers at 24 weeks. The cumulative number of participants developing UGI ulcers at 24 weeks was analyzed using the CMH test stratified by use of low-dose aspirin and prior UGI ulcer history.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>CMH test stratified by use of low-dose aspirin (yes/no) and prior UGI ulcer history (yes/no) at randomization.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>11.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.1</ci_lower_limit>
            <ci_upper_limit>17.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.</title>
        <description>The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HZT-501</title>
            <description>HZT-501: Ibuprofen 800mg/famotidine 26.6mg</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 800mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.</title>
          <description>The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="550"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="1.0" upper_limit="6.8"/>
                    <measurement group_id="O2" value="14" lower_limit="1.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The secondary efficacy endpoint was the number of participants developing duodenal ulcers throughout 24 weeks of treatment. A summary, including cumulative frequency and percentage with associated 95% confidence intervals was produced for the observational incidences of duodenal ulcers at 24 weeks. The cumulative number of participants developing duodenal ulcers at 24 weeks was analyzed using the CMH test stratified by use of low-dose aspirin and prio UGI ulcer history at randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>CMH test stratified by use of low-dose aspirin (yes/no) and prior UGI ulcer history (yes/no) at randomization.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Developing Non-steroidal Anti-inflammatory (NSAID)Associated Serious Gastrointestinal Complications (Perforation of Ulcers, Gastric Outlet Obstruction Due to Ulcers, Gastrointestinal Bleeding)</title>
        <description>The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HZT-501</title>
            <description>HZT-501: Ibuprofen 800mg/famotidine 26.6mg</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 800mg</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Developing Non-steroidal Anti-inflammatory (NSAID)Associated Serious Gastrointestinal Complications (Perforation of Ulcers, Gastric Outlet Obstruction Due to Ulcers, Gastrointestinal Bleeding)</title>
          <description>The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding.</description>
          <units>particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="550"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Randomization to 28 weeks.</time_frame>
      <desc>Safety Population: All randomized participants who received at least one dose of study drug and who underwent a baseline endoscopic examination. Participants were assigned to the treatment to which they received; 2:1 randomization, HZT-501:ibuprofen.</desc>
      <group_list>
        <group group_id="E1">
          <title>HZT-501</title>
          <description>HZT-501: Ibuprofen 800mg/famotidine 26.6mg</description>
        </group>
        <group group_id="E2">
          <title>Ibuprofen</title>
          <description>Ibuprofen 800mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 9.1">esoinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>hemorrhoid hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bronchits</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>cellulits</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>dyspnea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="342" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="184" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI reserves the right to publish or otherwise make public the Study results provided that such communication occurs only after (i) the results of the multicenter Study in its entirety have been publicly disclosed by, or with consent of the sponsor or (ii) 18 months after conclusion of the Study at all sites, whichever comes first. Following this, PI can publish, present or use any non-confidential study results following Sponsor review. PI will not make public raw data or Case Reports.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy Grahn, MS Senior Vice President, Clinical Development and Operations</name_or_title>
      <organization>Horizon Pharma, Inc.</organization>
      <phone>224-383-3012</phone>
      <email>agrahn@horizonpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

